These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 24004656)
21. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies. Giannì M; de Thé H Leukemia; 1999 May; 13(5):739-49. PubMed ID: 10374879 [TBL] [Abstract][Full Text] [Related]
22. Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line. Liu L; Li Y; Xiong X; Qi K; Zhang C; Fang J; Guo H Int J Oncol; 2016 Dec; 49(6):2319-2330. PubMed ID: 27840903 [TBL] [Abstract][Full Text] [Related]
23. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537 [TBL] [Abstract][Full Text] [Related]
24. Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line. Noh EK; Kim H; Park MJ; Baek JH; Park JH; Cha SJ; Won JH; Min YJ Leuk Res; 2010 Nov; 34(11):1501-5. PubMed ID: 20226526 [TBL] [Abstract][Full Text] [Related]
25. [Effects of arsenic trioxide on the subcellular localization of PML/PML-RARalpha protein in leukemic cells]. Ni J; Chen G; Zhu J; Zhong H; Tang W; Li X; Xiong S; Shen Z; Chen S; Wang Z; Chen L Zhonghua Xue Ye Xue Za Zhi; 1997 Jan; 18(1):32-4. PubMed ID: 15622748 [TBL] [Abstract][Full Text] [Related]
26. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. Lallemand-Breitenbach V; Zhu J; Puvion F; Koken M; Honoré N; Doubeikovsky A; Duprez E; Pandolfi PP; Puvion E; Freemont P; de Thé H J Exp Med; 2001 Jun; 193(12):1361-71. PubMed ID: 11413191 [TBL] [Abstract][Full Text] [Related]
27. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling. Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509 [TBL] [Abstract][Full Text] [Related]
29. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Ora I; Bondesson L; Jönsson C; Ljungberg J; Pörn-Ares I; Garwicz S; Pâhlman S Biochem Biophys Res Commun; 2000 Oct; 277(1):179-85. PubMed ID: 11027660 [TBL] [Abstract][Full Text] [Related]
30. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells. Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431 [TBL] [Abstract][Full Text] [Related]
31. As2O3-induced c-Src/EGFR/ERK signaling is via Sp1 binding sites to stimulate p21WAF1/CIP1 expression in human epidermoid carcinoma A431 cells. Liu ZM; Huang HS Cell Signal; 2006 Feb; 18(2):244-55. PubMed ID: 15961274 [TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816 [TBL] [Abstract][Full Text] [Related]
33. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688 [TBL] [Abstract][Full Text] [Related]
34. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926 [TBL] [Abstract][Full Text] [Related]
35. Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4. Bernardini S; Nuccetelli M; Noguera NI; Bellincampi L; Lunghi P; Bonati A; Mann K; Miller WH; Federici G; Lo Coco F Ann Hematol; 2006 Oct; 85(10):681-7. PubMed ID: 16733740 [TBL] [Abstract][Full Text] [Related]
36. [Experimental study of low dose arsenic trioxide in treatment of patients with acute promyelocytic leukemia]. Jia PM; Zhu Q; Yu Y; Chen GQ; Chen SJ; Chen Z; Wang ZY; Tong JH Ai Zheng; 2002 Apr; 21(4):337-40. PubMed ID: 12452006 [TBL] [Abstract][Full Text] [Related]
37. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. Zhang P J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942 [TBL] [Abstract][Full Text] [Related]
38. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Hayakawa F; Privalsky ML Cancer Cell; 2004 Apr; 5(4):389-401. PubMed ID: 15093545 [TBL] [Abstract][Full Text] [Related]
39. Restoration of promyelocytic leukemia protein-nuclear bodies in neuroblastoma cells enhances retinoic acid responsiveness. Yu JH; Nakajima A; Nakajima H; Diller LR; Bloch KD; Bloch DB Cancer Res; 2004 Feb; 64(3):928-33. PubMed ID: 14871822 [TBL] [Abstract][Full Text] [Related]
40. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Rojewski MT; Körper S; Schrezenmeier H Leuk Lymphoma; 2004 Dec; 45(12):2387-401. PubMed ID: 15621751 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]